As shown in Supplementary Fig. 18e‒h, quercetagitrin and ALDOA Y174/302/328A mutants effectively decreased the expression of Ki67 and LYVE-1 in tumor tissues; specifically, quercetagitrin could not further reduce the levels of these biomarkers in ESCC tumors harboring ALDOA Y174/302/328A mutants. This evidence concerns the gene LYVE1 and neoplasm.